AP NEWS
Click to copy
Press release content from BusinessWire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Tarveda Therapeutics to Present at the 2019 BIO CEO & Investor Conference

February 4, 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--Feb 4, 2019--Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 2019 BIO CEO & Investor Conference, occurring February 11-12, 2019 at the New York Marriot Marquis.

The presentation will take place at 2:15pm Eastern Time on Monday, February 11 in the Gramercy room.

In the presentation, Mr. Fromkin will provide an overview of the Company’s two clinical programs including PEN-221, which is currently in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) positive neuroendocrine tumors and PEN-866, the first miniature drug conjugate from Tarveda’s HSP90 binding conjugate platform, which is being developed for the treatment of patients with solid tumors including but not limited to small cell lung cancer, pancreatic cancer and sarcomas.

About Tarveda Therapeutics, Inc.

Tarveda Therapeutics, Inc. is discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors. Tarveda’s first drug candidate, PEN-221, is a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors. PEN-221 comprises a peptide that is highly selective for SSTR2 conjugated to the potent cytotoxic payload, DM1, through a tuned cleavable linker. Tarveda is also advancing its HSP90 binding drug conjugate platform with lead drug candidate PEN-866, which selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its SN-38 payload, a potent topoisomerase 1 inhibitor. Tarveda’s strategy includes developing its own proprietary miniature drug conjugates as well as applying its miniature drug conjugate platform to enhance the effectiveness of the targeting moieties and novel payloads of pharmaceutical collaborators. http://www.tarvedatx.com/

View source version on businesswire.com:https://www.businesswire.com/news/home/20190204005186/en/

CONTACT: Amanda Houlihan

MacDougall Biomedical Communications

781 235 3060

ahoulihan@macbiocom.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL GENERAL HEALTH

SOURCE: Tarveda Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 02/04/2019 08:00 AM/DISC: 02/04/2019 08:01 AM

http://www.businesswire.com/news/home/20190204005186/en

All contents Ā© copyright 2019 The Associated Press. All rights reserved.